Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 6/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.36 |
| ▸ | LPL | P06858 | 4/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21916943 | 0.93 | TNF (0.43) | TNF | |
| SCHEMBL21916914 | 0.88 | KMT2A (0.41) | LMNAKMT2ALIPGLPLUCHL1 | |
| SCHEMBL16465393 | 0.81 | LIPG (0.47) | LIPGLPL | |
| SCHEMBL506042 | 0.79 | LIPG (0.40) | LIPGLPLP4HB | |
| SCHEMBL25432068 | 0.79 | ALDH1A1 (0.36) | LIPGLPLP4HBALDH1A1 | |
| SCHEMBL21217742 | 0.78 | KDM4E (0.41) | LMNAMEN1KMT2ALIPGLPL | |
| SCHEMBL506778 | 0.78 | LPL (0.46) | LIPGLPL | |
| SCHEMBL506428 | 0.77 | LPL (0.38) | LIPGLPL | |
| SCHEMBL21730386 | 0.77 | LIPG (0.38) | LIPGLPLP4HB | |
| SCHEMBL15205597 | 0.76 | TNF (0.45) | CREBBPMEN1KMT2ATNFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717730-B1 | Dihydroisoquinoline compound | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| US-20200207755-A1 | DIHYDROISOQUINOLINE COMPOUND | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-10647712-B2 | Dihydroisoquinoline compound | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647712-B2 | Dihydroisoquinoline compound | HAVCR2, GLS2, GOT2 | LMNA 3026/4885CREBBP 1397/4885MEN1 2896/4885 |
| US-20200207755-A1 | DIHYDROISOQUINOLINE COMPOUND | GLS2, GOT1, GOT2 | LMNA 2335/4885CREBBP 1154/4885MEN1 3782/4885 |
| US-10717730-B1 | Dihydroisoquinoline compound | GLS2, GOT1, GOT2 | LMNA 2335/4885CREBBP 1154/4885MEN1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.